NASDAQ:CODX Co-Diagnostics Q4 2023 Earnings Report $0.35 -0.01 (-3.06%) As of 04/25/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings HistoryForecast Co-Diagnostics EPS ResultsActual EPS-$0.50Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ACo-Diagnostics Revenue ResultsActual Revenue$3.56 millionExpected Revenue$3.63 millionBeat/MissMissed by -$70.00 thousandYoY Revenue GrowthN/ACo-Diagnostics Announcement DetailsQuarterQ4 2023Date3/14/2024TimeN/AConference Call DateThursday, March 14, 2024Conference Call Time4:30PM ETUpcoming EarningsCo-Diagnostics' Q1 2025 earnings is scheduled for Thursday, May 8, 2025, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q1 2025 Earnings ReportConference Call ResourcesConference Call AudioConference Call TranscriptPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Co-Diagnostics Q4 2023 Earnings Call TranscriptProvided by QuartrMarch 14, 2024 ShareLink copied to clipboard.There are 5 speakers on the call. Operator00:00:00Good day, and welcome to the Co Diagnostics 4th Quarter and Full Year 2023 Earnings Conference Call. All participants will be in listen only mode. Please note this event is being recorded. I would now like to turn the conference over to Andrew Benson, Investor Relations. Please go ahead. Speaker 100:00:37Good afternoon, everyone. Thank you all for participating in today's conference call. On the line today from Co Diagnostics, we have Dwight Egan, Chief Executive Officer and Brian Brown, Chief Financial Officer. Earlier today, Co Diagnostics released financial results from the Q4 full year ended December 31, 2023. A copy of the press release is available on the company's website. Speaker 100:01:01We will begin the call with management's prepared remarks and then open the call to analyst Q and A. Before we begin, we would like to inform the listeners that certain statements made by Co Diagnostics during this call may constitute forward looking statements. Any statement about company expectations, beliefs, plans, objectives, assumptions of future events or performance are forward looking statements. For example, statements concerning 2024 financial and operational guidance, the development, regulatory clearance, commercialization and features of new products, plans and objectives of management and market trends are all forward looking statements. This includes statements concerning the company's forthcoming Kodiak's PCR testing platform, which requires regulatory approval and marketing authorization for diagnostic use, is currently being reviewed by the U. Speaker 100:01:48S. FDA and is currently not for sale. The company believes these statements are based on reasonable assumptions. However, these statements are not guarantees of performance and involve known and unknown risks and uncertainties that may cause the actual results to be materially different from any future results expressed or implied by such statements. Important factors which could cause actual results to differ materially from those in these forward looking statements are detailed in Co Diagnostics' filings with the SEC. Speaker 100:02:17Co Diagnostics assumes no obligation and expressly disclaims any duty to update any forward looking statements to reflect events or circumstances occurring after this call or to reflect the occurrence of unanticipated events. In addition, the company may discuss certain non GAAP financial measures during today's call. These non GAAP financial measures should not be considered a replacement for and should be read together with GAAP results. We refer you to the company's earnings release shortly before this call, which contains reconciliation to the non GAAP financial measures presented to their most comparable GAAP results. At this time, I would like to turn the call over to Co Diagnostics' Chief Executive Officer, Dwight Egan. Speaker 100:02:57Dwight? Speaker 200:03:00Thank you, Andrew. Good afternoon, everyone. Thank you all for joining Co Diagnostics' 4th quarter and full year 2023 earnings call. 2023 was an exciting year for Co Diagnostics as we expanded industry awareness of our CoPrimers technology and the Kodi X PCR platform. Throughout the year, we participated in several industry and investor conferences, where we spoke about the value proposition of our platform and our commercial and regulatory strategies. Speaker 200:03:34We also achieved several key milestones, including the receipt of several prestigious grants, the expansion of manufacturing capacity and an emergency use authorization submission to the FDA for the Kodiak's PCR Pro and Kodiak's PCR COVID-nineteen test kit. Today, we will provide an update on our Q4 and full year 2023 financial performance and discuss recent activities at the company as we continue to execute across our business and test developments. During the Q4, we were pleased to submit an emergency use authorization application to the FDA for our new KodiX PCR Pro instrument mobile app and KodiX COVID-nineteen test kit. Our easy to use real time PCR platform is differentiated by several exciting features and capabilities. Tests run on our instrument utilize Co Diagnostics unique patented co primers PCR technology. Speaker 200:04:43Co primers ensure reliability by providing higher quality test results through the significant reduction of primer dimers, which often lead to false positive results. The most notable feature of the platform is our cloud based analytics, which delivers test results from the instrument to the mobile app in just 30 minutes. The nature of our app also enables Kodiak's PCR real time HIPAA compliant integration into the EMR, which we anticipate will allow physicians, public health officials and even governments to examine and monitor results, tracking outbreaks in communities and countries around the globe. I am proud of the Co Diagnostics team for their collective efforts in finalizing our EUA submission, which we anticipate will be the first regulatory submission of many related to the new platform, and the importance of which is difficult to overstate. We are excited for the platform's first regulatory review, which includes several never before developers and regulatory experts who contributed to a strong regulatory submission for this platform, which we believe has the potential to revolutionize how and where infectious disease diagnostics take place. Speaker 200:06:12We also have already collected enough samples in the ongoing clinical evaluation to allow us to pursue a 510 clearance for our Kodiak's PCR Pro and Kodiak's COVID-nineteen test, which we anticipate will be submitted in the first half of this year. We look forward to providing you with more updates on this current regulatory review process as they become available. While we plan to initially launch the platform with our COVID test, we also have several other tests currently under development, including tuberculosis and upper respiratory multiplex, followed by HPV and strep throat. We plan to begin clinical evaluations for our TB test later this year in geographies where the disease is most prevalent. Specific clinical trial testing sites will be located in Africa, Australia and India, where we have a strong operational presence with our joint venture, COSERA Diagnostics. Speaker 200:07:16Tuberculosis is the most deadly disease in the world, and the eradication of TB remains a focal point for the World Health Organization or the WHO, as well as the Bill and Melinda Gates Foundation, from whom we have already received 2 grants to accelerate our TV platform and to expand manufacturing capacity. We plan to first pursue regulatory clearance for this test through 2 jurisdictions that are recognized by the WHO for diagnostics recommendations, the TGA or the Australian Regulatory Pathway Authority and the CDSCO in India. After these submissions, we plan to submit to the WHO for a recommendation. A recommendation from the WHO would aid in the commercialization of our TB test across many regions of the world, especially markets in Africa, where WHO recommendation is required before a test can be used as a diagnostic. Importantly, India, where we have domestic manufacturing and distribution capabilities with COSARA, is a large and underserved market. Speaker 200:08:29We believe that our platform and TB tests have the potential to dramatically improve the state of TB testing in India, where there are 69,000 hospitals, over 115,000 pharmacies and where roughly 220,000,000 people were screened for TB in 2021, according to the World Health Organization. In addition to TB, we have continued the development of the multiplex upper respiratory test with support from the NIH Radix Tech Grant. Co Diagnostics plans to initiate clinical evaluations during the next flu season later this year in order to collect sufficient data for an FDA submission. Another important indication of focus in our pipeline is our HPV test, which was also the subject of a Gates Foundation grant last year. HPV is an additional high priority infection for the WHO, as it remains the most common STI and the greatest risk factor for cervical cancer, which has many associated deaths in low income countries. Speaker 200:09:38Our development efforts for HPV are currently focused in India, where there is a significant underserved population. Lastly, with the CodeX COVID-nineteen test through the development stage and currently under FDA review, we have begun actively developing a strep throat test, which we believe has the potential to increase the attractiveness of the platform as a point of care solution. As we approach the launch of the Kodiak's PCR platform, we have begun to ramp our internal processes to ensure we are adequately prepared to serve our target markets. Over the past year, Co Diagnostics has made substantial investments to ensure that we have the appropriate infrastructure for commercialization, and we are fully prepared to begin scaling manufacturing pending authorization. The Kodiak's PCR Pro system has been designed for the point of care setting, and we plan to initially target U. Speaker 200:10:38S. Assisted living facilities, skilled nursing facilities and physicians' offices. We are prioritizing institutional settings where test volumes and overall demand remain high. We firmly believe that our highly accurate, accessible and low cost device can drive improved patient outcomes, both in institutional settings in the US and in low to middle income countries where accessibility to testing has been a consistent barrier in healthcare. While testing volumes have fallen from their peak in the height of the pandemic, COVID-nineteen is second only to tuberculosis in terms of lives lost every year, and it remains one of the most in demand tests worldwide. Speaker 200:11:25This includes for regions like India, Saudi Arabia and Australia, where we believe we will be able to begin commercializing the Kodiak's COVID-nineteen test following regulatory clearance or registration in those countries. We believe that our COVID-nineteen test will be the first of many indications on our Kodiak's PCR Pro instrument to serve the diagnostics market. As we expand to additional indications such as tuberculosis, we plan to market our platform even more broadly outside of the United States. A principal component of our successful commercialization launch strategy is increased manufacturing capacity. We have recently completed the build out of a new facility in Salt Lake City for both cups and instrument manufacturing with capacity to add additional lines for both, while we also continue to increase speed and efficiency. Speaker 200:12:23In addition, plans are in place and activity is underway in India, where COSARA is adding capacity to manufacture instruments and cup lines in country. Large scale manufacturing in India is not only an important aspect of our global ambitions to be able to serve Asian and African markets, but it is also required in order to qualify under the Make in India initiative. The Make in India initiative was launched nearly a decade ago to promote as a preferred global manufacturing destination and qualification under this initiative removes roadblocks to commercialization in India. We want to highlight that we are now producing our own oligonucleotides or co primers in Salt Lake City, which we believe will improve costs and efficiencies. We are also currently in the process of building in house co primers manufacturing primers manufacturing capacity at our manufacturing plant in India with support from the Gates Foundation grant. Speaker 200:13:24We are excited about these initiatives and the improvements that in house manufacturing will bring to co diagnostics and to patients around the world. Among our most prominent accomplishments in 2020 are the several grants that we received from organizations focused on solving the most pressing health issues in the world. The significant support that we received in the past year has enabled further development of tests in our pipeline, including our tuberculosis test, upper respiratory multiplex test and HPV test. The support and recognition that Co Diagnostics has received is a testament to the value proposition of our platform, including our technology, scientific team and approach and platform capabilities. We are currently in active discussions with other organizations and have implemented an internal team who is working diligently to drive the grant application process forward for co diagnostics. Speaker 200:14:25Before passing things over to Brian, I wanted to share a brief update with you regarding our attendance at industry and investor conferences in the Q4. In November, we presented at the Piper Sandler Conference, where we outlined our business strategy anchored around the development of the Kodiak's PCR platform and associated ongoing pipeline developmental efforts. Co Diagnostics also attended the Utah Life Sciences Summit and the Association For Molecular Pathology or AMP in Salt Lake City, in which we hosted a booth displaying our disruptive technology and delivered a presentation. We also attended the Consumer Electronics Show or CES in Las Vegas this January for the 2nd time. Outside the US, we had a very well attended booth at MedLab Africa where we discussed our development and commercial plans with many regional players. Speaker 200:15:20And earlier this year, we hosted a booth at MedLab Middle East 2024 in Dubai. Attending prominent industry events has allowed us to highlight our recent achievements and has given our team further confidence in our platform and how we can address underserved areas of the market and the productive conversations we have had with potential customers and distributors provide helpful feedback on our development pipeline and commercialization strategies. In 2024, we look forward to progressing our dialogue with prominent market constituents as we work towards our common goal of making diagnostics more accessible around the world. In closing, we are proud of our achievements in 2023 and look forward to an exciting 2024. We have developed an accurate, affordable and valuable point of care platform to help communities and patients across the globe. Speaker 200:16:16The company also remains well funded with $58,500,000 in cash, cash equivalents and marketable securities on our balance sheet. We look forward to updating you on our development and commercial progress throughout the year. Now, I will turn the call over to Brian to discuss our 4th quarter and full year 2023 financials in greater detail. Brian? Thanks, Dwight, and thanks to everyone who joined today's call. Speaker 200:16:44For fiscal year 2023, total revenue decreased to $6,800,000 as compared to $34,200,000 in the prior year same period. Grant revenue in 2023 was $5,800,000 Speaker 300:16:59and product revenue was $1,000,000 which declined year over year due to the impact of decreased global demand for COVID-nineteen testing. Gross profit for the full year 2023 decreased to $2,600,000 compared to $28,700,000 in the prior year. Total operating expenses for the year ended December 31, 2023 decreased to $45,300,000 compared to 55 point $7,000,000 in 2022. The decrease from the prior year is a result of goodwill impairment charges recorded in 2022, partially offset in 2023 by strategic investments in research and development to support our development and commercialization initiatives for our CodeX PCR platform. Research and development expenses in 2023 were $23,000,000 compared to 17 point $4,000,000 in the comparable prior year. Speaker 300:18:00The year over year increase was largely driven by investments in our CodeX PCR platform and COVID-nineteen tests ahead of our FDA submission, as well as ongoing developments of other tests in our pipeline. For 2023, income before taxes increased to a loss of $38,100,000 as compared to a loss of $18,800,000 reported in the prior year. We experienced an income tax benefit of $2,800,000 representing an effective tax rate of 7.3%. We have previously discussed that our effective tax rate will differ from the U. S. Speaker 300:18:38Federal statutory rate of 21.0 percent due to state taxes, permanent items and discrete items. Net loss for 2023 was $35,300,000 or a loss of $1.20 per fully diluted share compared to a net loss of $14,200,000 or a loss of $0.45 per fully diluted share in the prior year. Adjusted EBITDA for 2023 was a loss of $33,000,000 compared to an adjusted EBITDA loss of $3,100,000 in the prior year. We ended the year with $58,500,000 in cash, cash equivalents and marketable securities and continue to manage our spend as we look to maintain a healthy balance sheet to position ourselves for long term growth. For the full year 2023, we repurchased approximately 1,000,000 shares at an average price of $1.41 per share. Speaker 300:19:39As of December 31, 2023, we have repurchased just over 4,800,000 shares at an average share price of $3.21 per share for an aggregate amount of $15,600,000 within our $30,000,000 repurchase program. We continue to evaluate strategic share repurchase opportunities as we see fit. We are committed to maintaining a strong cash position through diligent expense management to ensure Co Diagnostics is well capitalized to execute on our long term growth initiatives. As we exited the year, we have continued to invest responsibly in our commercial initiatives to position the company for a successful commercial launch upon authorization or approval from the FDA. We remain well capitalized to deliver on our 2024 plan and are optimistic about the prospects for the Kodiak's PCR platform, first with COVID, followed by TB, upper respiratory multiplex and HPV. Speaker 300:20:42I look forward to updating you on our next earnings call. With that, I will now turn the presentation back over to Dwight. Speaker 200:20:50Thank you, Brian. Before opening for Q and A, I want to thank our Kodiak shareholders Speaker 300:20:56as Speaker 200:20:56well as our employees, distributors and consultants who strongly believe in our platform and the value that it offers. I look forward to updating you again next quarter. We will now take calls from our analysts. Operator? Operator00:21:11We will now begin the question and answer Our first question comes from Yi Chen with H. C. Wainwright. Please go ahead. Speaker 400:21:37Thank you for taking my questions. Could you comment on whether it has the FDA provided any feedback regarding the submission and when do the FDA to complete the review process? Thank you. Speaker 200:21:54Thanks for the question, Yi. The FDA is once we turned it over to the FDA and made our submission, the timeline is the FDA is to decide when they're going to respond to us. So we don't have any update currently on our submission. Speaker 400:22:20So after FDA approved the device, how soon can you launch the device in the U. S. And other global markets? Thank you. Speaker 200:22:33The company is prepared to launch the device immediately upon authorization from the FDA. So we have done a lot of work for some time now preparing to launch the product. So we're simply waiting for the FDA to give us authorization. Speaker 400:22:55Currently, could you comment on your expectation regarding potential sales in the U. S. And other geographic? Any rough estimates would be helpful. Thank you. Speaker 300:23:11Yes, Yi, this is Brian. We have not provided any formal guidance for 2024 given that our platform and product are still being reviewed by the FDA. And we're not prepared to provide any of that guidance either at this point in time. Speaker 400:23:28And last question is after the initial COVID test, how soon can the rest of the test, especially the multiplex test can secure clearance from the FDA? Speaker 200:23:45Yi, we expect to begin our clinical trials for our multiplex test, which as you know has grant support from the National Institute of Health through the RadixTech program and we expect to be able to commence our clinical trials during the upcoming flu season. So that flu season where we have to gather a certain number of samples, after that we will do the submission. I might also add that the COVID test which is currently under review by the FDA for emergency use authorization and we have already completed the infill testing for that and we have the sufficient samples to make a submission to the FDA for a full 510. We are concluding the evaluations and analytical work that together with the in field results comprise the total evaluation that will be submitted to the FDA, we believe, by sometime midyear. Speaker 400:25:07Got it. Thank you very much. Operator00:25:13This concludes our question and answer session. The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.Read morePowered by Conference Call Audio Live Call not available Earnings Conference CallCo-Diagnostics Q4 202300:00 / 00:00Speed:1x1.25x1.5x2x Earnings DocumentsPress Release(8-K)Annual report(10-K) Co-Diagnostics Earnings HeadlinesCo-Diagnostics price target lowered to $1 from $1.50 at H.C. WainwrightMarch 30, 2025 | markets.businessinsider.comCo-Diagnostics targets 2025 clinical evaluations for TB and HPV tests in India and South AfricaMarch 27, 2025 | msn.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.April 26, 2025 | Paradigm Press (Ad)Co-Diagnostics, Inc. (CODX) Q4 2024 Earnings Call TranscriptMarch 27, 2025 | seekingalpha.comCo-Diagnostics, Inc. Reports Full Year 2024 Financial ResultsMarch 27, 2025 | prnewswire.comUncovering Potential: Co-Diagnostics's Earnings PreviewMarch 27, 2025 | benzinga.comSee More Co-Diagnostics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Co-Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Co-Diagnostics and other key companies, straight to your email. Email Address About Co-DiagnosticsCo-Diagnostics (NASDAQ:CODX), a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.View Co-Diagnostics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Markets Think Robinhood Earnings Could Send the Stock UpIs the Floor in for Lam Research After Bullish Earnings?Market Anticipation Builds: Joby Stock Climbs Ahead of EarningsIs Intuitive Surgical a Buy After Volatile Reaction to Earnings?Seismic Shift at Intel: Massive Layoffs Precede Crucial EarningsRocket Lab Lands New Contract, Builds Momentum Ahead of EarningsAmazon's Earnings Could Fuel a Rapid Breakout Upcoming Earnings Cadence Design Systems (4/28/2025)Welltower (4/28/2025)Waste Management (4/28/2025)AstraZeneca (4/29/2025)Mondelez International (4/29/2025)PayPal (4/29/2025)Starbucks (4/29/2025)DoorDash (4/29/2025)Honeywell International (4/29/2025)Regeneron Pharmaceuticals (4/29/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
There are 5 speakers on the call. Operator00:00:00Good day, and welcome to the Co Diagnostics 4th Quarter and Full Year 2023 Earnings Conference Call. All participants will be in listen only mode. Please note this event is being recorded. I would now like to turn the conference over to Andrew Benson, Investor Relations. Please go ahead. Speaker 100:00:37Good afternoon, everyone. Thank you all for participating in today's conference call. On the line today from Co Diagnostics, we have Dwight Egan, Chief Executive Officer and Brian Brown, Chief Financial Officer. Earlier today, Co Diagnostics released financial results from the Q4 full year ended December 31, 2023. A copy of the press release is available on the company's website. Speaker 100:01:01We will begin the call with management's prepared remarks and then open the call to analyst Q and A. Before we begin, we would like to inform the listeners that certain statements made by Co Diagnostics during this call may constitute forward looking statements. Any statement about company expectations, beliefs, plans, objectives, assumptions of future events or performance are forward looking statements. For example, statements concerning 2024 financial and operational guidance, the development, regulatory clearance, commercialization and features of new products, plans and objectives of management and market trends are all forward looking statements. This includes statements concerning the company's forthcoming Kodiak's PCR testing platform, which requires regulatory approval and marketing authorization for diagnostic use, is currently being reviewed by the U. Speaker 100:01:48S. FDA and is currently not for sale. The company believes these statements are based on reasonable assumptions. However, these statements are not guarantees of performance and involve known and unknown risks and uncertainties that may cause the actual results to be materially different from any future results expressed or implied by such statements. Important factors which could cause actual results to differ materially from those in these forward looking statements are detailed in Co Diagnostics' filings with the SEC. Speaker 100:02:17Co Diagnostics assumes no obligation and expressly disclaims any duty to update any forward looking statements to reflect events or circumstances occurring after this call or to reflect the occurrence of unanticipated events. In addition, the company may discuss certain non GAAP financial measures during today's call. These non GAAP financial measures should not be considered a replacement for and should be read together with GAAP results. We refer you to the company's earnings release shortly before this call, which contains reconciliation to the non GAAP financial measures presented to their most comparable GAAP results. At this time, I would like to turn the call over to Co Diagnostics' Chief Executive Officer, Dwight Egan. Speaker 100:02:57Dwight? Speaker 200:03:00Thank you, Andrew. Good afternoon, everyone. Thank you all for joining Co Diagnostics' 4th quarter and full year 2023 earnings call. 2023 was an exciting year for Co Diagnostics as we expanded industry awareness of our CoPrimers technology and the Kodi X PCR platform. Throughout the year, we participated in several industry and investor conferences, where we spoke about the value proposition of our platform and our commercial and regulatory strategies. Speaker 200:03:34We also achieved several key milestones, including the receipt of several prestigious grants, the expansion of manufacturing capacity and an emergency use authorization submission to the FDA for the Kodiak's PCR Pro and Kodiak's PCR COVID-nineteen test kit. Today, we will provide an update on our Q4 and full year 2023 financial performance and discuss recent activities at the company as we continue to execute across our business and test developments. During the Q4, we were pleased to submit an emergency use authorization application to the FDA for our new KodiX PCR Pro instrument mobile app and KodiX COVID-nineteen test kit. Our easy to use real time PCR platform is differentiated by several exciting features and capabilities. Tests run on our instrument utilize Co Diagnostics unique patented co primers PCR technology. Speaker 200:04:43Co primers ensure reliability by providing higher quality test results through the significant reduction of primer dimers, which often lead to false positive results. The most notable feature of the platform is our cloud based analytics, which delivers test results from the instrument to the mobile app in just 30 minutes. The nature of our app also enables Kodiak's PCR real time HIPAA compliant integration into the EMR, which we anticipate will allow physicians, public health officials and even governments to examine and monitor results, tracking outbreaks in communities and countries around the globe. I am proud of the Co Diagnostics team for their collective efforts in finalizing our EUA submission, which we anticipate will be the first regulatory submission of many related to the new platform, and the importance of which is difficult to overstate. We are excited for the platform's first regulatory review, which includes several never before developers and regulatory experts who contributed to a strong regulatory submission for this platform, which we believe has the potential to revolutionize how and where infectious disease diagnostics take place. Speaker 200:06:12We also have already collected enough samples in the ongoing clinical evaluation to allow us to pursue a 510 clearance for our Kodiak's PCR Pro and Kodiak's COVID-nineteen test, which we anticipate will be submitted in the first half of this year. We look forward to providing you with more updates on this current regulatory review process as they become available. While we plan to initially launch the platform with our COVID test, we also have several other tests currently under development, including tuberculosis and upper respiratory multiplex, followed by HPV and strep throat. We plan to begin clinical evaluations for our TB test later this year in geographies where the disease is most prevalent. Specific clinical trial testing sites will be located in Africa, Australia and India, where we have a strong operational presence with our joint venture, COSERA Diagnostics. Speaker 200:07:16Tuberculosis is the most deadly disease in the world, and the eradication of TB remains a focal point for the World Health Organization or the WHO, as well as the Bill and Melinda Gates Foundation, from whom we have already received 2 grants to accelerate our TV platform and to expand manufacturing capacity. We plan to first pursue regulatory clearance for this test through 2 jurisdictions that are recognized by the WHO for diagnostics recommendations, the TGA or the Australian Regulatory Pathway Authority and the CDSCO in India. After these submissions, we plan to submit to the WHO for a recommendation. A recommendation from the WHO would aid in the commercialization of our TB test across many regions of the world, especially markets in Africa, where WHO recommendation is required before a test can be used as a diagnostic. Importantly, India, where we have domestic manufacturing and distribution capabilities with COSARA, is a large and underserved market. Speaker 200:08:29We believe that our platform and TB tests have the potential to dramatically improve the state of TB testing in India, where there are 69,000 hospitals, over 115,000 pharmacies and where roughly 220,000,000 people were screened for TB in 2021, according to the World Health Organization. In addition to TB, we have continued the development of the multiplex upper respiratory test with support from the NIH Radix Tech Grant. Co Diagnostics plans to initiate clinical evaluations during the next flu season later this year in order to collect sufficient data for an FDA submission. Another important indication of focus in our pipeline is our HPV test, which was also the subject of a Gates Foundation grant last year. HPV is an additional high priority infection for the WHO, as it remains the most common STI and the greatest risk factor for cervical cancer, which has many associated deaths in low income countries. Speaker 200:09:38Our development efforts for HPV are currently focused in India, where there is a significant underserved population. Lastly, with the CodeX COVID-nineteen test through the development stage and currently under FDA review, we have begun actively developing a strep throat test, which we believe has the potential to increase the attractiveness of the platform as a point of care solution. As we approach the launch of the Kodiak's PCR platform, we have begun to ramp our internal processes to ensure we are adequately prepared to serve our target markets. Over the past year, Co Diagnostics has made substantial investments to ensure that we have the appropriate infrastructure for commercialization, and we are fully prepared to begin scaling manufacturing pending authorization. The Kodiak's PCR Pro system has been designed for the point of care setting, and we plan to initially target U. Speaker 200:10:38S. Assisted living facilities, skilled nursing facilities and physicians' offices. We are prioritizing institutional settings where test volumes and overall demand remain high. We firmly believe that our highly accurate, accessible and low cost device can drive improved patient outcomes, both in institutional settings in the US and in low to middle income countries where accessibility to testing has been a consistent barrier in healthcare. While testing volumes have fallen from their peak in the height of the pandemic, COVID-nineteen is second only to tuberculosis in terms of lives lost every year, and it remains one of the most in demand tests worldwide. Speaker 200:11:25This includes for regions like India, Saudi Arabia and Australia, where we believe we will be able to begin commercializing the Kodiak's COVID-nineteen test following regulatory clearance or registration in those countries. We believe that our COVID-nineteen test will be the first of many indications on our Kodiak's PCR Pro instrument to serve the diagnostics market. As we expand to additional indications such as tuberculosis, we plan to market our platform even more broadly outside of the United States. A principal component of our successful commercialization launch strategy is increased manufacturing capacity. We have recently completed the build out of a new facility in Salt Lake City for both cups and instrument manufacturing with capacity to add additional lines for both, while we also continue to increase speed and efficiency. Speaker 200:12:23In addition, plans are in place and activity is underway in India, where COSARA is adding capacity to manufacture instruments and cup lines in country. Large scale manufacturing in India is not only an important aspect of our global ambitions to be able to serve Asian and African markets, but it is also required in order to qualify under the Make in India initiative. The Make in India initiative was launched nearly a decade ago to promote as a preferred global manufacturing destination and qualification under this initiative removes roadblocks to commercialization in India. We want to highlight that we are now producing our own oligonucleotides or co primers in Salt Lake City, which we believe will improve costs and efficiencies. We are also currently in the process of building in house co primers manufacturing primers manufacturing capacity at our manufacturing plant in India with support from the Gates Foundation grant. Speaker 200:13:24We are excited about these initiatives and the improvements that in house manufacturing will bring to co diagnostics and to patients around the world. Among our most prominent accomplishments in 2020 are the several grants that we received from organizations focused on solving the most pressing health issues in the world. The significant support that we received in the past year has enabled further development of tests in our pipeline, including our tuberculosis test, upper respiratory multiplex test and HPV test. The support and recognition that Co Diagnostics has received is a testament to the value proposition of our platform, including our technology, scientific team and approach and platform capabilities. We are currently in active discussions with other organizations and have implemented an internal team who is working diligently to drive the grant application process forward for co diagnostics. Speaker 200:14:25Before passing things over to Brian, I wanted to share a brief update with you regarding our attendance at industry and investor conferences in the Q4. In November, we presented at the Piper Sandler Conference, where we outlined our business strategy anchored around the development of the Kodiak's PCR platform and associated ongoing pipeline developmental efforts. Co Diagnostics also attended the Utah Life Sciences Summit and the Association For Molecular Pathology or AMP in Salt Lake City, in which we hosted a booth displaying our disruptive technology and delivered a presentation. We also attended the Consumer Electronics Show or CES in Las Vegas this January for the 2nd time. Outside the US, we had a very well attended booth at MedLab Africa where we discussed our development and commercial plans with many regional players. Speaker 200:15:20And earlier this year, we hosted a booth at MedLab Middle East 2024 in Dubai. Attending prominent industry events has allowed us to highlight our recent achievements and has given our team further confidence in our platform and how we can address underserved areas of the market and the productive conversations we have had with potential customers and distributors provide helpful feedback on our development pipeline and commercialization strategies. In 2024, we look forward to progressing our dialogue with prominent market constituents as we work towards our common goal of making diagnostics more accessible around the world. In closing, we are proud of our achievements in 2023 and look forward to an exciting 2024. We have developed an accurate, affordable and valuable point of care platform to help communities and patients across the globe. Speaker 200:16:16The company also remains well funded with $58,500,000 in cash, cash equivalents and marketable securities on our balance sheet. We look forward to updating you on our development and commercial progress throughout the year. Now, I will turn the call over to Brian to discuss our 4th quarter and full year 2023 financials in greater detail. Brian? Thanks, Dwight, and thanks to everyone who joined today's call. Speaker 200:16:44For fiscal year 2023, total revenue decreased to $6,800,000 as compared to $34,200,000 in the prior year same period. Grant revenue in 2023 was $5,800,000 Speaker 300:16:59and product revenue was $1,000,000 which declined year over year due to the impact of decreased global demand for COVID-nineteen testing. Gross profit for the full year 2023 decreased to $2,600,000 compared to $28,700,000 in the prior year. Total operating expenses for the year ended December 31, 2023 decreased to $45,300,000 compared to 55 point $7,000,000 in 2022. The decrease from the prior year is a result of goodwill impairment charges recorded in 2022, partially offset in 2023 by strategic investments in research and development to support our development and commercialization initiatives for our CodeX PCR platform. Research and development expenses in 2023 were $23,000,000 compared to 17 point $4,000,000 in the comparable prior year. Speaker 300:18:00The year over year increase was largely driven by investments in our CodeX PCR platform and COVID-nineteen tests ahead of our FDA submission, as well as ongoing developments of other tests in our pipeline. For 2023, income before taxes increased to a loss of $38,100,000 as compared to a loss of $18,800,000 reported in the prior year. We experienced an income tax benefit of $2,800,000 representing an effective tax rate of 7.3%. We have previously discussed that our effective tax rate will differ from the U. S. Speaker 300:18:38Federal statutory rate of 21.0 percent due to state taxes, permanent items and discrete items. Net loss for 2023 was $35,300,000 or a loss of $1.20 per fully diluted share compared to a net loss of $14,200,000 or a loss of $0.45 per fully diluted share in the prior year. Adjusted EBITDA for 2023 was a loss of $33,000,000 compared to an adjusted EBITDA loss of $3,100,000 in the prior year. We ended the year with $58,500,000 in cash, cash equivalents and marketable securities and continue to manage our spend as we look to maintain a healthy balance sheet to position ourselves for long term growth. For the full year 2023, we repurchased approximately 1,000,000 shares at an average price of $1.41 per share. Speaker 300:19:39As of December 31, 2023, we have repurchased just over 4,800,000 shares at an average share price of $3.21 per share for an aggregate amount of $15,600,000 within our $30,000,000 repurchase program. We continue to evaluate strategic share repurchase opportunities as we see fit. We are committed to maintaining a strong cash position through diligent expense management to ensure Co Diagnostics is well capitalized to execute on our long term growth initiatives. As we exited the year, we have continued to invest responsibly in our commercial initiatives to position the company for a successful commercial launch upon authorization or approval from the FDA. We remain well capitalized to deliver on our 2024 plan and are optimistic about the prospects for the Kodiak's PCR platform, first with COVID, followed by TB, upper respiratory multiplex and HPV. Speaker 300:20:42I look forward to updating you on our next earnings call. With that, I will now turn the presentation back over to Dwight. Speaker 200:20:50Thank you, Brian. Before opening for Q and A, I want to thank our Kodiak shareholders Speaker 300:20:56as Speaker 200:20:56well as our employees, distributors and consultants who strongly believe in our platform and the value that it offers. I look forward to updating you again next quarter. We will now take calls from our analysts. Operator? Operator00:21:11We will now begin the question and answer Our first question comes from Yi Chen with H. C. Wainwright. Please go ahead. Speaker 400:21:37Thank you for taking my questions. Could you comment on whether it has the FDA provided any feedback regarding the submission and when do the FDA to complete the review process? Thank you. Speaker 200:21:54Thanks for the question, Yi. The FDA is once we turned it over to the FDA and made our submission, the timeline is the FDA is to decide when they're going to respond to us. So we don't have any update currently on our submission. Speaker 400:22:20So after FDA approved the device, how soon can you launch the device in the U. S. And other global markets? Thank you. Speaker 200:22:33The company is prepared to launch the device immediately upon authorization from the FDA. So we have done a lot of work for some time now preparing to launch the product. So we're simply waiting for the FDA to give us authorization. Speaker 400:22:55Currently, could you comment on your expectation regarding potential sales in the U. S. And other geographic? Any rough estimates would be helpful. Thank you. Speaker 300:23:11Yes, Yi, this is Brian. We have not provided any formal guidance for 2024 given that our platform and product are still being reviewed by the FDA. And we're not prepared to provide any of that guidance either at this point in time. Speaker 400:23:28And last question is after the initial COVID test, how soon can the rest of the test, especially the multiplex test can secure clearance from the FDA? Speaker 200:23:45Yi, we expect to begin our clinical trials for our multiplex test, which as you know has grant support from the National Institute of Health through the RadixTech program and we expect to be able to commence our clinical trials during the upcoming flu season. So that flu season where we have to gather a certain number of samples, after that we will do the submission. I might also add that the COVID test which is currently under review by the FDA for emergency use authorization and we have already completed the infill testing for that and we have the sufficient samples to make a submission to the FDA for a full 510. We are concluding the evaluations and analytical work that together with the in field results comprise the total evaluation that will be submitted to the FDA, we believe, by sometime midyear. Speaker 400:25:07Got it. Thank you very much. Operator00:25:13This concludes our question and answer session. The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.Read morePowered by